Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10502)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2015 (publication date) through May 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol 2015; 7(15): 1964-1970 [PMID: 26244070 DOI: 10.4254/wjh.v7.i15.1964] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i15/1964.htm |
| Number | Citing Articles |
| 1 |
Roberto Mazzanti, Umberto Arena, Renato Tassi. Hepatocellular carcinoma: Where are we?. World Journal of Experimental Medicine 2016; 6(1): 21-36 doi: 10.5493/wjem.v6.i1.21
|
| 2 |
Mohammed Y. Alhassani, Samir F. Zohny, Ryan A. Sheikh, Mohammed A. Hassan, Abdulaziz A. Kalantan, Salman Hosawi, Mahmoud Alhosin. Thymoquinone exerts anti-tumor activities on human hepatocellular carcinoma cells: role of angiogenesis-related genes VCAN, Grb2 and EZH2. European Journal of Cell Science 2019; : 10 doi: 10.34154/2019-EJCS-0101-10-16/euraass
|
| 3 |
Abdulsalam Alhalmi, Sarwar Beg, Kanchan Kohli, Md. Waris, Tanuja Singh. Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting. Current Drug Targets 2021; 22(7): 779 doi: 10.2174/1389450121999201209194524
|
| 4 |
Liberatore Tramontano, Carlo Cavaliere, Marco Salvatore, Valentina Brancato. The Role of Non-Gaussian Models of Diffusion Weighted MRI in Hepatocellular Carcinoma: A Systematic Review. Journal of Clinical Medicine 2021; 10(12): 2641 doi: 10.3390/jcm10122641
|
| 5 |
Alok R. Singh, Shweta Joshi, Adam M. Burgoyne, Jason K. Sicklick, Sadakatsu Ikeda, Yuko Kono, Joseph R. Garlich, Guillermo A. Morales, Donald L. Durden. Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2016; 15(11): 2553 doi: 10.1158/1535-7163.MCT-15-0976
|
| 6 |
Wei-Chieh Huang, Shiao-Lin Tung, Yao-Li Chen, Po-Ming Chen, Pei-Yi Chu. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4529-9
|
| 7 |
Yongqi Ding, Yiyang Gong, Hong Zeng, Gelin Song, Zichuan Yu, Bidong Fu, Yue Liu, Da Huang, Yanying Zhong. ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility. Aging 2023; 15(13): 6179 doi: 10.18632/aging.204827
|
| 8 |
Ali Alqahtani, Zubair Khan, Abdurahman Alloghbi, Tamer S. Said Ahmed, Mushtaq Ashraf, Danae M. Hammouda. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina 2019; 55(9): 526 doi: 10.3390/medicina55090526
|
| 9 |
Bao-Kang Wu, Qian-Hui Chen, Dan Pan, Bing Chang, Li-Xuan Sang. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. International Immunopharmacology 2021; 96: 107790 doi: 10.1016/j.intimp.2021.107790
|
| 10 |
Paulo H. C. Diniz, Serena D. C. Silva, Paula V. T. Vidigal, Marcelo A. P. Xavier, Cristiano X. Lima, Luciana C. Faria, Teresa C. A. Ferrari, Liren Qian. Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma. Journal of Oncology 2020; 2020: 1 doi: 10.1155/2020/4609360
|
| 11 |
Lili Cao, Lijun Zhang, Xiang Zhao, Ye Zhang, Daolin Tang. A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLOS ONE 2016; 11(8): e0161025 doi: 10.1371/journal.pone.0161025
|
| 12 |
Ganxin Wang, Bai Wei, Qian Ma, Shu Huang, Qi Wu. Effects of sorafenib and regorafenib on the expression of hypoxia-inducible factors in hepatocellular carcinoma-transplanted nude mice. Oncology and Translational Medicine 2022; 8(5): 259 doi: 10.1007/s10330-021-0546-6
|
| 13 |
Vito Longo, Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Sabina Delcuratolo, Riccardo Memeo, Antonio Giovanni Solimando, Antonella Argentiero. Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina 2019; 55(10): 698 doi: 10.3390/medicina55100698
|
| 14 |
Aya Takahashi, Atsushi Umemura, Kota Yano, Shinya Okishio, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh. Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.707473
|
| 15 |
Henghui Cheng, Jin Xue, Shouhua Yang, Yaobin Chen, Yu Wang, Yuanli Zhu, Xiaoyan Wang, Dong Kuang, Qiurong Ruan, Yaqi Duan, Guoping Wang. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget 2017; 8(29): 47984 doi: 10.18632/oncotarget.18207
|
| 16 |
Yusha Xiao, Baiyang Chen, Kang Yang, Quanxiong Wang, Pengpeng Liu, Yang Gu, Qiu Zhong, Zhisu Liu, Yueming He, Quanyan Liu. Down-regulation of MARCO associates with tumor progression in hepatocellular carcinoma. Experimental Cell Research 2019; 383(2): 111542 doi: 10.1016/j.yexcr.2019.111542
|
| 17 |
Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro. Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer. Translational Oncology 2021; 14(9): 101158 doi: 10.1016/j.tranon.2021.101158
|
| 18 |
Jiale Ju, Yinghua Wu, Wen He, Lin Zhan, Xuelian Yin, Junfeng Zhang, Yuxi Zhang, Li Qiu, Pir Muhammad, Rui L. Reis, Chenchen Li. Nanocarriers for Active Ingredients of Chinese Medicine (AIFCM) Used in Gastrointestinal Cancer Therapy. Journal of Biomedical Nanotechnology 2022; 18(10): 2279 doi: 10.1166/jbn.2022.3446
|
| 19 |
Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.686962
|
| 20 |
Baiyang Chen, Yang Gu, Hui Shen, Qiangsheng Liu, Hongbo Wang, Yabo Li, Xifan Liu, Yu Liu, Qinghao Du, Huapeng Sun, Xiaofeng Liao. Borealin Promotes Tumor Growth and Metastasis by Activating the Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2022; : 171 doi: 10.2147/JHC.S336452
|
| 21 |
Jamshid Motalebzadeh, Elaheh Eskandari. Transcription factors linked to the molecular signatures in the development of hepatocellular carcinoma on a cirrhotic background. Medical Oncology 2021; 38(10) doi: 10.1007/s12032-021-01567-x
|
| 22 |
Hyuk Moon, Simon Weonsang Ro. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers 2021; 13(12): 3026 doi: 10.3390/cancers13123026
|
| 23 |
Jin Chen, Zhao-qi Zhang, Jia Song, Qiu-meng Liu, Chao Wang, Zhao Huang, Liang Chu, Hui-fang Liang, Bi-xiang Zhang, Xiao-ping Chen. 18β-Glycyrrhetinic-acid-mediated unfolded protein response induces autophagy and apoptosis in hepatocellular carcinoma. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-27142-5
|
| 24 |
Xiaofeng Yuan, Ming Zhuang, Xi Zhu, Dong Cheng, Jie Liu, Donglin Sun, Xubin Qiu, Yunjie Lu, Kurt Sartorius. Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.943866
|
| 25 |
Zhi Fu, Guang Yang, Tiezheng Wang, Daming Gao, Dongdong Lin, Xiaoni Liu.
Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma
. Journal of Environmental Pathology, Toxicology and Oncology 2023; 42(4): 47 doi: 10.1615/JEnvironPatholToxicolOncol.2023045721
|
| 26 |
Yu Zhou, Yang Liu, Chao Hu, Yugang Jiang. MicroRNA-16 inhibits the proliferation, migration and invasion of glioma cells by targeting Sal-like protein 4. International Journal of Molecular Medicine 2016; 38(6): 1768 doi: 10.3892/ijmm.2016.2775
|
| 27 |
Jing Li, Jinfeng Wang, Wei Zhou, Shuqin Zhang, Yuan Le, Rong He. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncology Letters 2017; 14(4): 4751 doi: 10.3892/ol.2017.6770
|
| 28 |
Fanghua Qiu, Huajing Long, Lu Zhang, Jieyuan Liu, Zetian Yang, Xianzhang Huang. Dermcidin Enhances the Migration, Invasion, and Metastasis of Hepatocellular Carcinoma Cells In Vitro and In Vivo. Journal of Clinical and Translational Hepatology 2022; 10(3): 429 doi: 10.14218/JCTH.2021.00108
|
| 29 |
Gokhan Yildiz. Integrated multi‑omics data analysis identifying novel drug sensitivity‑associated molecular targets of hepatocellular carcinoma cells. Oncology Letters 2018; doi: 10.3892/ol.2018.8634
|
| 30 |
Mao Zhang, Shun Zhang, Zhenjie Yang, Jie Hu, Weiyu Hu, Peng Sun, Liqun Wu, Bing Han. Association between the expression levels of IL‑6 and IL‑6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncology Letters 2018; doi: 10.3892/ol.2018.9557
|
| 31 |
Jin Chen, Haidan Zhu, Qiumeng Liu, Deng Ning, Zhaoqi Zhang, Long Zhang, Jie Mo, Pengcheng Du, Xu Liu, Shasha Song, Yawei Fan, Huifang Liang, Jikui Liu, Bixiang Zhang, Xiaoping Chen. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1220-1
|
| 32 |
Shuli Man, Chen Luo, Mengyao Yan, Ganggang Zhao, Long Ma, Wenyuan Gao. Treatment for liver cancer: From sorafenib to natural products. European Journal of Medicinal Chemistry 2021; 224: 113690 doi: 10.1016/j.ejmech.2021.113690
|
| 33 |
Meiwan Chen, Xingzhi Zhou, Ruie Chen, Junlin Wang, Richard D. Ye, Yitao Wang, Chuanbin Wu, Ram I. Mahato. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019; 25: 66 doi: 10.1016/j.mattod.2018.10.040
|
| 34 |
Hyuk Moon, Hyunjung Park, Min Jee Chae, Hye Jin Choi, Do Young Kim, Simon Weonsang Ro. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09516-1
|
| 35 |
Ishfaq Hassan Mir, Shreyoshi Guha, Jajnasenee Behera, Chinnasamy Thirunavukkarasu. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biology International 2021; 45(11): 2161 doi: 10.1002/cbin.11670
|
| 36 |
Sara Hooshmand, Mohammad Reza Mahdinezhad, Shirin Taraz Jamshidi, Mohammad Soukhtanloo, Farshad Mirzavi, Mehrdad Iranshahi, Maedeh Hasanpour, Ahmad Ghorbani. Morus nigra L. extract prolongs survival of rats with hepatocellular carcinoma. Phytotherapy Research 2021; 35(6): 3365 doi: 10.1002/ptr.7056
|
| 37 |
MINORU TOMIZAWA, FUMINOBU SHINOZAKI, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO, NAOKI ISHIGE. Suppression of hepatocellular carcinoma cell proliferation by short hairpin RNA of frizzled 2 with Sonazoid-enhanced irradiation. International Journal of Oncology 2016; 48(1): 123 doi: 10.3892/ijo.2015.3259
|
| 38 |
Emanuele Rinninella, Lucia Cerrito, Irene Spinelli, Marco Cintoni, Maria Cristina Mele, Maurizio Pompili, Antonio Gasbarrini. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology 2017; (XX): 1 doi: 10.14218/JCTH.2017.00002
|
| 39 |
Ahmed G. Abd Elhameed, Manar G. Helal, Eman Said, Hatem A. Salem. Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: A novel suppressive impact on Wnt/Hedgehog/Notch1 signaling. Environmental Toxicology and Pharmacology 2021; 86: 103668 doi: 10.1016/j.etap.2021.103668
|
| 40 |
Qiaoxin Huang, Shengsong He, Dongang Zhan. Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax. Journal of Cancer Research and Clinical Oncology 2023; 149(12): 10727 doi: 10.1007/s00432-023-04926-5
|
| 41 |
Weiyi Zhu, Xiangjun Dong, Na Tian, Zijuan Feng, Weihui Zhou, Weihong Song. CSTB accelerates the progression of hepatocellular carcinoma via the ERK/AKT/mTOR signaling pathway. Heliyon 2024; 10(1): e23506 doi: 10.1016/j.heliyon.2023.e23506
|
| 42 |
Caroline Lefeuvre, Hélène Le Guillou-Guillemette, Alexandra Ducancelle. A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis. International Journal of Molecular Sciences 2021; 22(24): 13651 doi: 10.3390/ijms222413651
|
| 43 |
Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Vito Longo, Angela Calabrese, Antonella Argentiero, Sabina Delcuratolo, Antonio Giovanni Solimando, Andrea Casadei-Gardini, Nicola Silvestris. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina 2019; 55(10): 707 doi: 10.3390/medicina55100707
|
| 44 |
Lin Ji, Zhongjie Lin, Zhe Wan, Shunjie Xia, Shi Jiang, Dong Cen, Liuxin Cai, Junjie Xu, Xiujun Cai. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death & Disease 2020; 11(4) doi: 10.1038/s41419-020-2413-4
|
| 45 |
Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research 2021; 9(1) doi: 10.1186/s40364-021-00319-3
|
| 46 |
Rafia Shekh, Rohit Kumar Tiwari, Afza Ahmad, Irfan Ahmad, Nadiyah M. Alabdallah, Mohd Saeed, Irfan Ahmad Ansari, Anuradha Mishra, Mohammad Ashfaque, Preeti Bajpai.
Ethanolic extract of
Coleus aromaticus
leaves impedes the proliferation and instigates apoptotic cell death in liver cancer HepG2 cells through repressing JAK/STAT cascade
. Journal of Food Biochemistry 2022; 46(10) doi: 10.1111/jfbc.14368
|
| 47 |
Hu Li, Pengbo Hu, Yajun Zou, Lijuan Yuan, Yucheng Xu, Xiaohui Zhang, Xiaoyan Luo, Zhiqiang Zhang. Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1071415
|
| 48 |
Yu Wang, Baocheng Deng. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer and Metastasis Reviews 2023; 42(3): 629 doi: 10.1007/s10555-023-10084-4
|
| 49 |
Awik Puji Dyah Nurhayati, Adik Mayang Indiani, Evira Nadila Oktyasti, Mardi Santoso, Edwin Setiawan, Nurul Jadid, Muhamad Amin. Molecular docking and pharmacophore analysis of trisindoline 1 against human topoisomerase II and human derived growth factor. THE 7TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, AND MEDICAL DEVICES: The 15th Asian Congress on Biotechnology in conjunction with the 7th International Symposium on Biomedical Engineering (ACB-ISBE 2022) 2024; 3080: 060004 doi: 10.1063/5.0200770
|
| 50 |
MINORU TOMIZAWA, FUMINOBU SHINOZAKI, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO, NAOKI ISHIGE. Suppressive effects of 3-bromopyruvate on the proliferation and the motility of hepatocellular carcinoma cells. Oncology Reports 2016; 35(1): 59 doi: 10.3892/or.2015.4370
|
| 51 |
Tania Mariastella Caputo, Angela Maria Cusano, Menotti Ruvo, Anna Aliberti, Andrea Cusano. Human Serum Albumin Nanoparticles as a Carrier for On-Demand
Sorafenib Delivery. Current Pharmaceutical Biotechnology 2022; 23(9): 1214 doi: 10.2174/1389201022666210826152311
|
| 52 |
Na Lu, Jiali Min, Lin Peng, Shengjian Huang, Xiahua Chai, Susu Wang, Jian Wang. MiR-297 inhibits tumour progression of liver cancer by targeting PTBP3. Cell Death & Disease 2023; 14(8) doi: 10.1038/s41419-023-06097-0
|
| 53 |
Jian Pu, Jianchu Wang, Wenchuan Li, Yuan Lu, Xianjian Wu, Xidai Long, Chunying Luo, Huamei Wei. hsa_circ_0000092 promotes hepatocellular carcinoma progression through up‐regulating HN1 expression by binding to microRNA‐338‐3p. Journal of Cellular and Molecular Medicine 2024; 28(6) doi: 10.1111/jcmm.15010
|
| 54 |
Rossella Fasano, Mahdi Abdoli Shadbad, Oronzo Brunetti, Antonella Argentiero, Angela Calabrese, Patrizia Nardulli, Roberto Calbi, Behzad Baradaran, Nicola Silvestris. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life 2021; 11(12): 1355 doi: 10.3390/life11121355
|
| 55 |
Fares E.M. Ali, Islam M. Ibrahim, Hanan S. Althagafy, Emad H.M. Hassanein. Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review. International Immunopharmacology 2024; 132: 112011 doi: 10.1016/j.intimp.2024.112011
|
| 56 |
Jiuwei Zhang, Yaodong Chen, Jing Lin, Ruimei Jia, Tingting An, Tianxiu Dong, Yu Zhang, Xiuhua Yang. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA and Cell Biology 2020; 39(3): 355 doi: 10.1089/dna.2019.4990
|
| 57 |
Bijay Dhungel, Charmaine A. Ramlogan-Steel, Jason C. Steel. Synergistic and independent action of endogenous microRNAs 122a and 199a for post-transcriptional liver detargeting of gene vectors. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-33801-4
|
| 58 |
Mahfoozur Rahman, Waleed H Almalki, Majed Alrobaian, Jawed Iqbal, Saad Alghamdi, Khalid S Alharbi, Nabil K Alruwaili, Abdul Hafeez, Adil Shaharyar, Tanuja Singh, Mohammad Waris, Vikas Kumar, Sarwar Beg. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opinion on Drug Delivery 2021; 18(4): 489 doi: 10.1080/17425247.2021.1854223
|
| 59 |
MINORU TOMIZAWA, FUMINOBU SHINOZAKI, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO, NAOKI ISHIGE. FH535 suppresses the proliferation and motility of hepatocellular carcinoma cells. International Journal of Oncology 2016; 48(1): 110 doi: 10.3892/ijo.2015.3220
|
| 60 |
Qinggang Tian, Yao Xiao, Yanting Wu, Yun Liu, Zhiqing Song, Wenfeng Gao, Jing Zhang, Jingling Yang, Yuguo Zhang, Tuankui Guo, Furong Dai, Zhigang Sun. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression. International Journal of Molecular Medicine 2016; 38(5): 1587 doi: 10.3892/ijmm.2016.2754
|
| 61 |
Jian-Min Qin. Postoperative recurrent factors and therapeutic and preventive strategies for hepatocellular carcinoma. World Chinese Journal of Digestology 2019; 27(23): 1407 doi: 10.11569/wcjd.v27.i23.1407
|
| 62 |
Bei Li, Yi Fu, Maodi Xie, Lei Feng, Xiaoya Niu, Lin Que, Zhen You. Gold-based nanoparticles realize photothermal and photodynamic synergistic treatment of liver cancer and improve the anaerobic tumor microenvironment under near-infrared light. Frontiers in Bioengineering and Biotechnology 2022; 10 doi: 10.3389/fbioe.2022.957349
|
| 63 |
Feng Liu, Wen Zhang, Fusheng Yang, Tingting Feng, Meng Zhou, Yuan Yu, Xiuping Yu, Weiming Zhao, Fan Yi, Wei Tang, Yi Lu. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Scientific Reports 2016; 6(1) doi: 10.1038/srep21260
|
| 64 |
Adriana Unić, Lovorka Derek, Marko Duvnjak, Leonardo Patrlj, Mislav Rakić, Milan Kujundžić, Vesna Renjić, Nikola Štoković, Petra Dinjar, Anita Jukic, Ivica Grgurević. Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 2018; 55(3): 355 doi: 10.1177/0004563217726808
|
| 65 |
Qunying Zhuang, Tengjian Zhou, Chengyong He, Shili Zhang, Yang Qiu, Bing Luo, Ran Zhao, Hengchuan Liu, Yuchun Lin, Zhongning Lin. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b. Journal of Experimental & Clinical Cancer Research 2016; 35(1) doi: 10.1186/s13046-016-0341-z
|
| 66 |
Hyuk Moon, Simon Weonsang Ro. Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. Journal of Liver Cancer 2021; 21(1): 1 doi: 10.17998/jlc.21.1.1
|
| 67 |
Kai Zheng, Chenghui Liao, Yan Li, Xinmin Fan, Long Fan, Hong Xu, Qiangrong Kang, Yong Zeng, Xuli Wu, Haiqiang Wu, Lizhong Liu, Xiaohua Xiao, Jian Zhang, Yifei Wang, Zhendan He. Gypenoside L, Isolated from Gynostemma pentaphyllum, Induces Cytoplasmic Vacuolation Death in Hepatocellular Carcinoma Cells through Reactive-Oxygen-Species-Mediated Unfolded Protein Response. Journal of Agricultural and Food Chemistry 2016; 64(8): 1702 doi: 10.1021/acs.jafc.5b05668
|
| 68 |
Dong Jiang, Xia-Ling Zhu, Yan An, Yi-ran Li. Clinical significance of small nuclear ribonucleoprotein U1 subunit 70 in patients with hepatocellular carcinoma. PeerJ 2024; 12: e16876 doi: 10.7717/peerj.16876
|
| 69 |
Hong-Mei Wu, Yuan-Yuan Huang, Yu-Qiu Xu, Wei-Lai Xiang, Chang Yang, Ru-Yuan Liu, Di Li, Xue-Feng Guo, Zheng-Bao Zhang, Chun-Hua Bei, Sheng-Kui Tan, Xiao-Nian Zhu. Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(2): 475-492 doi: 10.4251/wjgo.v16.i2.475
Abstract(127) |
Core Tip(115) |
Full Article(HTML)(758)
|
Full Article with Cover (PDF)-21849K(46)
|
Full Article (Word)-9845K(16)
|
Audio-436K(19)
|
Peer-Review Report-175K(19)
|
Answering Reviewers-96K(18)
|
Full Article (PDF)-21582K(44)
|
Full Article (XML)-152K(37)
|
Times Cited (0)
|
Total Visits (1841)
|
Open
|
| 70 |
Hongsheng Dang, Wuzhou Wu, Bo Wang, Cao Cui, Juwei Niu, Jie Chen, Ziqiu Chen, Yi Liu. CXCL5 Plays a Promoting Role in Osteosarcoma Cell Migration and Invasion in Autocrine- and Paracrine-Dependent Manners. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2017; 25(2): 177 doi: 10.3727/096504016X14732772150343
|
| 71 |
Abdullah M. Alnuqaydan, Abdulmajeed Almutary, Gh Rasool Bhat, Tanveer Ahmad Mir, Shadil Ibrahim Wani, Mohd Younis Rather, Shabir Ahmad Mir, Bader Alshehri, Sulaiman Alnasser, Faten M. Ali Zainy, Bilal Rah. Evaluation of the Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects of Withaferin A (WA) against Lipopolysaccharide (LPS)-Induced Inflammation in Immune Cells Derived from BALB/c Mice. Pharmaceutics 2022; 14(6): 1256 doi: 10.3390/pharmaceutics14061256
|
| 72 |
Manali Dimri, Ande Satyanarayana. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers 2020; 12(2): 491 doi: 10.3390/cancers12020491
|
| 73 |
Baiyang Chen, Jianwei Lan, Yusha Xiao, Pengpeng Liu, Deliang Guo, Yang Gu, Youai Song, Qiu Zhong, Dong Ma, Ping Lei, Quanyan Liu. Long noncoding RNA TP53TG1 suppresses the growth and metastasis of hepatocellular carcinoma by regulating the PRDX4/β-catenin pathway. Cancer Letters 2021; 513: 75 doi: 10.1016/j.canlet.2021.04.022
|
| 74 |
Lingxi Jiang, Qian Yan, Shuo Fang, Ming Liu, Yan Li, Yun‐Fei Yuan, Yan Li, Yinghui Zhu, Jiali Qi, Xiaodong Yang, Dora Lai Wan Kwong, Xin‐Yuan Guan. Calcium‐binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal‐regulated kinase signaling pathway. Hepatology 2017; 66(5): 1529 doi: 10.1002/hep.29312
|
| 75 |
Maha Fezza, Mayssam Moussa, Rita Aoun, Rita Haber, George Hilal, Masaru Katoh. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1. PLOS ONE 2019; 14(9): e0223252 doi: 10.1371/journal.pone.0223252
|
| 76 |
Jingjing Wang, Luyao Sun, Jie Liu, Bing Sun, Li Li, Zhi Ping Xu. Biomimetic 2D layered double hydroxide nanocomposites for hyperthermia-facilitated homologous targeting cancer photo-chemotherapy. Journal of Nanobiotechnology 2021; 19(1) doi: 10.1186/s12951-021-01096-9
|
| 77 |
Debolina Pal, Chinmay Kumar Panda. Cancer Diagnostics and Therapeutics. 2022; : 211 doi: 10.1007/978-981-16-4752-9_9
|
| 78 |
Yinying Dong, Xiaoyun Shen, Mingyan He, Zhifeng Wu, Qiongdan Zheng, Yaohui Wang, Yuhan Chen, Sifan Wu, Jiefeng Cui, Zhaochong Zeng. Activation of the JNK-c-Jun pathway in response to irradiation facilitates Fas ligand secretion in hepatoma cells and increases hepatocyte injury. Journal of Experimental & Clinical Cancer Research 2016; 35(1) doi: 10.1186/s13046-016-0394-z
|
| 79 |
Şirin Yüksel, Cemaliye Boylu Akyerli, M. Cengiz Yakıcıer. Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer 2017; 48(3): 256 doi: 10.1007/s12029-017-9962-5
|
| 80 |
Yi Xiao, Qiang Gong, Wenhong Wang, Fang Liu, Qinghong Kong, Feng Pan, Xiaoke Zhang, Changyan Yu, Shanshan Hu, Fang Fan, Sanhua Li, Yun Liu. The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma. Cancer Cell International 2020; 20(1) doi: 10.1186/s12935-020-01463-w
|
| 81 |
Rongliang Tong, Beng Yang, Heng Xiao, Chuanhui Peng, Wendi Hu, Xiaoyu Weng, Shaobing Cheng, Chengli Du, Zhen Lv, Chaofeng Ding, Lin Zhou, Haiyang Xie, Jian Wu, Shusen Zheng. KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling. Oncotarget 2017; 8(23): 37717 doi: 10.18632/oncotarget.17145
|
| 82 |
Abbasi Majid, Jinxia Wang, Muhammad Nawaz, Sattar Abdul, Munawar Ayesha, Chunmei Guo, Qinglong Liu, Shuqing Liu, Ming-Zhong Sun. miR-124-3p Suppresses the Invasiveness and Metastasis of Hepatocarcinoma Cells via Targeting CRKL. Frontiers in Molecular Biosciences 2020; 7 doi: 10.3389/fmolb.2020.00223
|
| 83 |
Shuchang Lou, Weili Sun, Yuan Wu. Biochemical overview of the recent findings on the correlation between viral hepatitis and its related hepatocellular carcinoma. Oncology and Translational Medicine 2018; 4(6): 229 doi: 10.1007/s10330-018-0305-5
|
| 84 |
Anna Ju, Young-Chang Cho, Ba Kim, Sewoong Lee, Hien Thi Le, Huong Vuong, Sayeon Cho. Anticancer effects of methanol extract of Myrmecodia platytyrea Becc. leaves against human hepatocellular carcinoma cells via inhibition of ERK and STAT3 signaling pathways. International Journal of Oncology 2017; doi: 10.3892/ijo.2017.4178
|
| 85 |
Chunmei Guo, Chao Gao, Dongting Zhao, Jiahui Li, Jinxia Wang, Xujuan Sun, Qinlong Liu, Lihong Hao, Frederick T. Greenaway, Yuxiang Tian, Shuqing Liu, Ming-Zhong Sun. A novel ETV6-miR-429-CRKL regulatory circuitry contributes to aggressiveness of hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2020; 39(1) doi: 10.1186/s13046-020-01559-1
|
| 86 |
Fahimeh Tabakhiyan, Amirabbas Mir, Vahid Vahedian. Potential tumor marker for hepatocellular carcinoma identification: PI3K and pro-inflammatory cytokines (TGF-β, IL-1, and IL-6). Hormone Molecular Biology and Clinical Investigation 2022; 43(4): 389 doi: 10.1515/hmbci-2022-0028
|
| 87 |
Yuan Chi, Zheng Gong, He Xin, Ziwen Wang, Zhaoyu Liu. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. Cell Cycle 2022; 21(24): 2651 doi: 10.1080/15384101.2022.2108275
|
| 88 |
Alessia Ferrarini, Cristina Di Poto, Shisi He, Chao Tu, Rency S. Varghese, Abdalla Kara Balla, Meth Jayatilake, Zhenzhi Li, Kian Ghaffari, Ziling Fan, Zaki A. Sherif, Deepak Kumar, Alexander Kroemer, Mahlet G. Tadesse, Habtom W. Ressom. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma. Journal of Proteome Research 2019; 18(8): 3067 doi: 10.1021/acs.jproteome.9b00185
|
| 89 |
Mohammed Nihal Hasan, Hani Choudhry, Syed Shoeb Razvi, Said Salama Moselhy, Taha Abduallah Kumosani, Mazin A. Zamzami, Ziad Omran, Majed A. Halwani, Salim Al-Babili, Khalid Omer Abualnaja, Abdulrahman Labeed Al-Malki, Mahmoud Alhosin, Tadao Asami. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells. Bioorganic & Medicinal Chemistry Letters 2018; 28(6): 1077 doi: 10.1016/j.bmcl.2018.02.016
|
| 90 |
Elisavet Lioulia, Panagiotis Mokos, Emmanuel Panteris, Dimitra Dafou. UBE2T promotes β‐catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK‐dependent activation. Molecular Oncology 2022; 16(8): 1694 doi: 10.1002/1878-0261.13111
|
| 91 |
Julen Sanz-Serrano, Ellen Callewaert, Sybren De Boever, Annika Drees, Anouk Verhoeven, Mathieu Vinken. Chemical-induced liver cancer: an adverse outcome pathway perspective. Expert Opinion on Drug Safety 2024; 23(4): 425 doi: 10.1080/14740338.2024.2326479
|
| 92 |
Xiao-Qin He, Yue-Feng Zhang, Jia-Jun Yu, Yuan-Yuan Gan, Na-Na Han, Mei-Xia Zhang, Wei Ge, Jun-Jian Deng, Yong-Fa Zheng, Xi-Ming Xu. High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumor Biology 2017; 39(3): 101042831769597 doi: 10.1177/1010428317695971
|
| 93 |
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh. JAK/STAT signaling in hepatocellular carcinoma. Hepatic Oncology 2020; 7(1) doi: 10.2217/hep-2020-0001
|